Theodore Kamenecka

Theodore Kamenecka, Ph.D., is the senior scientific director of the Department of Molecular Medicine at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology. He earned his Ph.D. in chemistry from the University of California, Irvine, in 1996, and completed his postdoctoral training at the Memorial Sloan Kattering Cancer Center in 1998. Dr. Kamenecka’s research interest is in the design, synthesis, and evaluation of novel compounds of biological and therapeutic interest. His group is currently involved in the designed and synthesis of novel small molecule modulators of nuclear receptors, GPCR’s, ion channels, kinases and mitochondria for the treatment of addiction, diabetes and obesity, multiple sclerosis, cognitive health, and aging. Working closely with other departments, his group optimizes lead compounds for potency, ADME (absorption, distribution, metabolism, and excretion), safety pharmacology, and toxicology to generate compounds suitable for preclinical development. Dr. Kamenecka is the co-founder of Eolas Therapeutics and Myosin Therapeutics.